Atransen Pharma Ltd. (APL) is a preclinical stage biotech developing APL1101 as a novel anti-tumor drug for solid tumor.

The target molecule is the amino acid transporter 1 (LAT1) selectively expressed in the surface of tumor cells, acting as a source of essential amino acids and promotes the mTORC1 pathway, critical for tumor cell growth.

APL has been selected as:

1. AMED pharmaceutical-startup ecosystem strengthening program (7th) in Japan

2. supported company for Nakanoshima Drug Discovery Cluster Campus Project  in Japan

3. Berkeley SkyDeck IPP (19th)

and the SeriesA (JP) funding has been closed in 2025.

APL is also seeking the SeriesB (JP), Series A(US) funding to start the global phase 1/2a clinical trial in JP/US by the end of 2026.

APL also has a potent pipeline of APL1202 for Boron Neutron Capture Therapy (BNCT).

APL1202 is intended for enabling BNCT to deep-seated tumor like pancreatic cancer etc.